1 The Egyptian IVFET Center, 3 St 161 Hadaek El Maadi, Maadi, Cairo 11431 and 2 Andrology and STDs Department, Faculty of Medicine Cairo University, Cairo, Egypt
3 To whom correspondence should be addressed. e-mail: ifahmy{at}idsc.net.eg
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: azoospermia/hypogonadotrophic hypogonadism/ICSI/testicular sperm extractionu
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Following the first reports of ICSI in humans, it has now become the standard treatment for severe male factor infertility (Mansour, 1998). In addition to the use of ejaculated sperm, azoospermic patients can be treated successfully with ICSI using surgically retrieved sperm from the epididymis or the testis.
The use of new assisted reproductive techniques in combination with medical treatment for hypogonadotrophic hypogonadism is rarely reported in the literature, as most pregnancies occur spontaneously once semen parameters improve. Pregnancies after IVF using sperm from patients with Kallmanns syndrome have been reported (van de Berk et al., 1991; Tournaye et al., 1992
; Smith et al., 1993
). Yong et al. (1997
) described a case of idiopathic hypogonadotrophic hypogonadism of post-pubertal onset where early intervention with ICSI using ejaculated sperm was attempted following 9 months of gonadotrophin therapy. Although three embryos were transferred, no pregnancy resulted. Medical therapy continued, with a subsequent spontaneous pregnancy after 16 months of treatment. The authors concluded that ICSI procedures should be delayed until final testicular maturation. In another case series including 42 patients, three of the 28 pregnancies (10.7%) resulted from the use of ICSI (Büchter et al., 1998
). The authors did not mention the total number of patients who underwent ICSI.
The aim of this study is to report the use of testicular sperm for ICSI in azoospermic males with hypogonadotrophic hypogonadism unresponsive to gonadotrophin therapy.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Before inclusion in our ICSI programme, all patients received 75 IU hMG thrice weekly and 5000 IU hCG once or twice weekly for 6 months. The dose of hCG was adjusted according to the testosterone level. Normal serum teststerone concentration in the adult male lies between 12 and 40 nmol/ml (Behre et al., 2001
). Semen analysis was performed every 3 months. Only patients who remained azoospermic after hormonal treatment were offered the treatment option of TESE/ICSI. All patients agreed through a written consent to the procedure. They were informed about all risks of transmitting infertility problems to their offspring.
General, pelvic examination and transvaginal ultrasonography were routinely performed on all female partners and no abnormalities were found. Routine laboratory tests including liver and kidney function tests were performed. Ovulation induction was performed using GnRH analogue protocol. Ovarian stimulation and oocyte retrieval ICSI were performed as described previously (Mansour et al., 1994).
TESE procedure
Open testicular biopsies were performed under local infiltration anaesthesia using a mixture of 1:1 bupovacaine and lidocaine as previously described (Fahmy et al., 1997). A rapid search for sperm was done, and, if no sperm suitable for injection were found, another biopsy was taken either from the same site or from other sites. If still no sperm were found, another biopsy was performed from the other testis. An extra piece of testicular tissue was obtained, fixed in Bouins solution and was used later to prepare 4 µm thin paraffin sections stained with haematoxylin and eosin. The collected pieces of testicular tissues were minced in a 200500 µl droplet of HEPES-buffered Earles medium (Medicult, Denmark) in a Petri dish (Falcon, cat. No. 3001; Becton Dickinson, UK) using two G28 needles. Micro-droplets from the suspension of minced testicular tissues were directly transferred to the injection dish and placed carefully in the micro-droplets previously prepared under mineral oil in an injection dish. The micro-droplets containing the suspension of the minced testicular tissue were examined carefully under the inverted phase microscope. If no sperm were found after a rapid search, the rest of the testicular tissue suspension was distributed in the injection dish and examined carefully for 23 h by at least two embryologists who searched for sperm. The injected oocytes were checked the next morning for 2-pronuclear formation and the embryo transfer was done on day 2 or 3 after ovum retrieval.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Nine patients continued gonadotrophin therapy for another 6 months. Sperm appeared in the ejaculate of three of them. The remaining six patients underwent another ICSI cycle, one using cryopreserved sperm and five underwent a second TESE. In all patients, sperm could be retrieved. In two patients, sperm could be readily retrieved without any need for prolonged search compared to a more difficult first TESE with excess sperm cryopreserved for future trials. One chemical pregnancy and three clinical pregnancies were established, resulting in the delivery of three normal offspring one is still ongoing. Two of the three patients with sperm appearing in the ejaculate dropped out from the study. The remaining patient continued on hormonal therapy and clinical pregnancy was achieved following ICSI, resulting in a normal male. Figure 1 illustrates the flow chart of our study and its outcome.
|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The protocols used for treatment of hypogonadotrophic hypogonadism vary widely. Two thousand international units of hCG may be given up to three times weekly for 36 months either alone or with 150 IU hMG (European Metrodin HP Study Group, 1998). Pulsatile GnRH therapy is also used for hypothalamic disorders, but its advantage over gonadotrophins is debated. Some reports show improved results with GnRH and others show no difference (Schopohl, 1993
; Liu et al., 1988
). This variation may be due to wide differences in the individual response to treatment. Testicular maldescent and small testicular volume are generally considered as negative prognostic factors (Ley and Leonard, 1985
). However, other authors suggest that maldescended testes do not necessarily produce poor response to treatment (Saal et al., 1991
). Even in patients who initially have a very small testicular volume, successful therapy is possible (Büchter et al., 1998
). A positive response to hormonal treatment in patients with hypogonadotrophic hypogonadism may be related to residual function of the pituitary gland that varies individually (Shargil, 1987
).
Most studies emphasize the need for long-term treatment in hypogonadotrophic hypogonadism. However, the retrospective nature of much of the work in this area makes assessment of the rate of the non-compliance and the true success rate rather difficult. Those patients discontinuing treatment at early stages are unlikely to be included in retrospective studies, which primarily look at long-term outcomes such as initiation of spermatogenesis and pregnancy. A positive response to hCG/hMG combinations as shown by positive sperm count varies between 40 and 70% (Vicari et al., 1992; Schopohl, 1993
; Liu et al., 1988
). In a large prospective study carried out on men with hypogonadotrophic hypogonadism, an overall response rate of (80%) was reported (Burgues et al., 1997
).
In our study, continuous gonadotrophin therapy was given for 6 months before offering assisted conception. The absence of a significant increase in testicular size and the persistence of azoospermia marked the unresponsiveness to hormonal treatment. This poor response may be related to initial small-sized testes and increased patients age. FSH, through its effect on Sertoli cells and bloodtesticular barrier, has an important role in the control of testicular microvascularity (Causio et al., 2002
). Repeated interrupted cycles of hormonal treatment can, therefore, lead to testicular fibrotic changes. This may deter any expected future effect of hormonal therapy. In the present study, all patients gave history of intermittent hormonal therapy, which in our opinion may have contributed to slow response observed after hormonal treatment. It is of note that gross tubular hyalinization was seen in the testicular histopathology of three patients. The fertilization rate (41.7%) and the pregnancy rate per ICSI cycle (17.6%) are both significantly lower than our previously reported rates in obstructive cases, 57.9 and 34.5% respectively, and very similar to those reported in patients with non-obstructive azzospermia, 41.2 and 16.6% respectively (Fahmy et al., 1997
).
Because hormonal treatment for hypogonadotrophic hypogonadism necessitates long periods of drug intake, compliance of the patients is considered an issue of substantial importance. Eight (53%) out of 15 patients dropped out from the study. Two patients dropped out despite the appearance of sperm in their ejaculate following 12 months of hormonal therapy. Although prolonged hormonal treatment in patients with hypogonadotrophic hypogonadism may result in better sperm retrieval rates and perhaps even normal pregnancy (Yong et al., 1997), we think that an early offer of assisted conception to patients with hypogonadotrophic hypogonadism under hormonal treatment at an earlier stage can increase patients compliance.
In conclusion, sperm appear in the testes long before their appearance in semen in patients with hypogonadotrophic hypogonadism under HRT. ICSI using testicular sperm can be offered to obtain pregnancy for patients who are either not responding or reluctant to continue hormonal treatment to avoid patient non-compliance. However, prolonged hormonal treatment should be encouraged for the longest possible period to improve TESE/ICSI results.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Büchter D, Behre, H, Kleish S and Nieshlag E (1998) Pulsatile GnRH or human chorionic gonadotrophin/human menopausal gonadotrophin as effective treatment for men with hypogonadotrophic hypogonadism: a review of 42 cases. Eur J Endocrinol 139,298303.[Medline]
Burgues S, Caldèron MD and the Spanish Collaborative Group on Male Hypogonadotrophic Hypogonadism (1997) Subcutaneous self-administration of highly purified follicle stimulating hormone and human chorionic gonadotrophin for the treatment of male hypogonadotrophic hypogonadism. Hum Reprod 12,980986.[CrossRef][Medline]
Causio F, Matteo, M, Cicinelli E, Cardo G, Angel, G and Pagliarulo A (2002) Variation of intratesticular blood flow in response to urinary follicle-stimulating hormone with chorionic gonadotropin for treating men with hypogonadotrophic hypogonadism. Fertil Steril 78,11331135.[CrossRef][Medline]
European Metrodin HP Study Group (1998) Efficacy and safety of highly purified urinary follicle-stimulating hormone with chorionic gonadotropin for treating men with isolated hypogonadotrophic hypogonadism. Fertil Steril 70,256262.[CrossRef][Medline]
Fahmy I, Mansour RT, Aboulghar MA, Serour G, Kamal A, Tawab NA, Ramzy AM and Amin Y (1997) Intracytoplasmic sperm injection using surgically retrieved epididymal and testicular spermatozoa in cases of obstructive and non-obstructive azoospermia. Int J Androl 20,3744.[CrossRef][Medline]
Finkel DM, Philips, JL and Snyder PJ (1985) Stimulation of spermatogenesis by gonadotrophins in men with hypogonadotrophic hypogonadism. N Eng J Med 313,651655.[Abstract]
Hoffman AR and Crowley WF Jr (1982) Induction of puberty in men by long-term pulsatile administration of low-dose gonadotrophin-releasing hormone. N Eng J Med 11,12371241.
Ley SB and Leonard JM (1985) Male hypogonadotrophic hypogonadism: factors influencing response to human chorionic gonadotrophin and human menopausal gonadotrophin, including prior oxygenous androgens. J Clin Endocrinol Metab 61,746752.[Abstract]
Liu L, Banks SM, Barnes, KM and Sherins, RJ (1988) Two year comparison of testicular responses to pulsatile gonadotrophin-releasing hormone and exogenous gonadotrophins from the inception of therapy in men with isolated hypogonadotrophic hypogonadism. J Clin Endocrinol Metab 67,11401145.[Abstract]
Mansour RT (1998) Intracytoplasmic sperm injection: a state of the art technique. Hum Reprod Update 4, 4356.
Mansour RT, Aboulghar MA and Serour GI (1994) Study of the optimum time for human chorionic gonadotrophin-ovum pick-up interval in in-vitro fertilization. J Assist Reprod Genet 11,428448.[Medline]
Meitinger T, Heye B, Petit C, Levilliers J, Golla A, Moraine C, Dalla Picolla B, Sippel WG, Murken J and Ballabio A (1990) Definitive localization of X-linked Kallmann syndrome (hypogonadotrophic hypogonadism and anosmia) to Xp22.3: close linkage to the hypervariable repeat sequence CRI-S232. Am J Hum Genet 47, 664669.[Medline]
Meschede D and Horst J (1999) Neue Erkenntinisse zur Genetik des Kallmann-Sydroms und des Idiopathischen Hypogonadotropen Hypogonadismus. Geburtsch Frauenheilkd 59,381385.[CrossRef]
Saal W, Happ J, Cordes U, Baum RP and Schmidt M (1991) Subcutaneous gonadotrophin therapy in male patients with hypogonadotrophic hypogonadism. Fertil Steril 56,31924.[Medline]
Schopohl J (1993) Pulsatile gonadotrophin releasing hormone versus gonadotrophin treatment of hypothalamic hypogonadism in males. Hum Reprod 8(Suppl 2),175179.[Abstract]
Seminara SB, Hayes FJ and Crowley WF (1998) Gonadotrophin-releasing hormone deficiency in human (idiopathic hypogonadotrophic hypogonadism): pathophysiological and genetic considerations. Endocr Rev 19,521539.
Shargil AA (1987) Treatment of idiopathic hypogonadotrophic hypogonadism in men with lutenizing hormone-releasing hormone: a comparison of treatment with daily injections and with the pulsatile infusion pump. Fertil Steril 47,492501.[Medline]
Smith YR, Ansbacher R, Christman GM, Hurd WW and Randolph JF Jr (1993) Kallmanns syndrome: pregnancy achieved through gamete intrafallopian transfer. Fertil Steril 60,737739.[Medline]
Tournaye, H., Van Sterteghem A and Devroey P (1992) Pregnanacy after zygote intra-fallopian transfer using spermatozoa from a patient with Kallmanns syndrome. Hum Reprod 7,12681270.[Abstract]
vandeBerk D, Wijnberg M and van Dop PA (1991) Initiation os spermatogenesis and successful in vitro fertilization in an infertile male with panhypopituitarism; superiority of pulsatile LH_RH over gonadotrophins? A case report. Eur J Obstet Gynecol Reprod Biol 40,153157.[Medline]
Vicari E, Mongioi A, Calogero AE, Mocada ML, Sidoti G, Polosa P and DAgata R (1992) Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism long-term follow-up. Int J Androl 15,320329.[Medline]
Waldstreicher J, Seminara SB, Jameson Jl, Geyer A, Nachtigall LB, Boepple PA, Holmes LB and Crowley WF (1996) The genetic and clinical heterogenecity of gonadotrophin-releasing hormone deficiency in humans. J Clin Endocinol Metab 81,43884395.[Abstract]
Yong EL, Lee KO, Ng SC and Ratnam SS (1997) Induction of spermatogenesis in isolated hypogonadotrophic hypogonadism with gonadotrophins and early intervention with intracytoplasmic sperm injection. Hum Reprod 12,12301232.[CrossRef][Medline]
Submitted on December 2, 2003; accepted on March 8, 2004.
|